Manufacturer:
Pfizer
Route of Administration:
Subcutaneous
Site of Care:
Outpatient
Website:
phone:
1-877-744-5675
Approved Indication:
to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
Therapeutic Area:
- Oncology